Copied to clipboard!

I-BCT-1 (Improved Breast Cancer Therapy) - WES

A prospective, randomized neoadjuvant study that evaluates DNA-based biomarkers to identify breast cancer patients most likely to benefit from carboplatin (Cb). While Cb improves outcomes in triple-negative breast cancer (TNBC), responses vary, and its role in aggressive hormone receptor–positive breast cancer (HR+BC) remains uncertain. Patients (N = 187) with early, high-risk, HER2-negative cT2-4 tumors received 12 weekly paclitaxel with or without Cb, followed by four cycles of epirubicin and cyclophosphamide. Transcriptomic analysis data for the tumor samples in this study is available in the matching Study titled I-BCT-1 (Improved Breast Cancer Therapy) - WXS.

Type: Exome Sequencing
Archive: Federated EGA Norway Federated EGA Node

1 Dataset

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000003091	This dataset comprises DNA whole-exome sequencing from a prospective, randomized neoadjuvant trial designed to evaluate DNA-based biomarkers for predicting carboplatin response in patients with early, high-risk breast cancer. The study enrolled 196 patients with with high-risk features, including triple-negative breast cancer (TNBC) and hormone receptor-positive (HR+) breast cancer subtypes. The final analysis included 187 patients, for which WES data is being made available for controlled access. Sample Composition Total samples: 373 (186 blood/normal + 187 tumor) - Blood samples: 186 (germline/reference) - Tumor samples: 187 (tumor tissue biopsies) Technical Specifications - Sequencing platform: Illumina HiSeq4000 - Read type: Paired-end - Read length: 2 × 76 bp - Library preparation: Twist Bioscience Human Comprehensive Exome Plus RefSeq v1 hybrid selection - DNA input: 100 ng per sample - Mean sequencing coverage: 46× for normal samples; 106× for tumor samples	Illumina HiSeq 4000	373